Aleksandra Suchołbiak

Aleksandra Suchołbiak

Auto-generated profile, based on publicly available information

Aleksandra Suchołbiak

Infant Jesus Clinical Hospital, Warsaw, Poland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2025 in Biuletyn Głównej Biblioteki Lekarskiej
Verified
Journal Article
Open access
PDF file
ASAleksandra Suchołbiak
Aleksandra Suchołbiak
OMOskar Mikołajczyk
Oskar Mikołajczyk
ASAleksandra Serafin
Aleksandra Serafin
UJUrszula JarzęCka
Urszula JarzęCka
Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental condition that has a significant impact on daily functioning in various areas of life. While pharmacology is the primary treatment, non-pharmacological interventions such as structured physical activities, particularly martial arts, are gaining prominence. This review evaluates the effectiveness of martial arts as a supportive intervention in ADHD. In addition, through this review, we aim to suggest possible approaches for future research in this area. Current results from randomized controlled clinical trials indicate that martial arts training can positively affect ADHD-related symptoms by improving visuospatial working memory, selective attention, inhibitory control, and processing speed. The results suggest that martial arts could potentially serve as a complementary intervention for ADHD, however, at this moment the body of research supporting this thesis is insufficient. We highlight the necessity for further research to strengthen current evidence, increase knowledge of additional potential benefits, standardize protocols, and optimize training methodologies.

9 July 2025 in Quality in Sport
Verified
Journal Article
Open access
PDF file
ASAleksandra Serafin
Aleksandra Serafin
ASAleksandra Suchołbiak
Aleksandra Suchołbiak
KBKarolina Baran
Karolina Baran
MPMaja Podolak
Maja Podolak
KPKlaudia Pachulska
Klaudia Pachulska
OMOskar Mikołajczyk
Oskar Mikołajczyk
Introduction: Hepatoepithelioid hemangioendothelioma (HEHE) is a rare, low-grade malignant vascular tumor that can occur in multiple parts of the body but primarily affects the liver. It is marked by the presence of endothelial cells showing characteristics of both vascular and epithelial cells. The tumor typically appears as a vascularized tumor, displaying different levels of abnormal cell features. Despite developing and improving diagnostic methods, misdiagnosis remains a challenge due to its overlapping features with other tumors which primarily affect the liver. Aim of Study: This review aims to summarize current knowledge on the clinical and radiological manifestations, diagnostic challenges, and treatment managements of HEHE with a focus on surgical therapies and possible signs of recurrence. Materials and Methods: A comprehensive review of the literature on hepatoepithelioid hemangioendothelioma was performed using the PubMed database. Results and Conclusions: Hepatoepithelioid hemangioendothelioma progression is unpredictable, as both benign and malignant variants can occur. Due to its rarity and variability in both clinical and radiological presentation, accurate diagnosis of this tumor is challenging for clinicians. Currently, there is no universally accepted standard treatment protocol as a consequence of low prevalence of HEHE. Despite this, liver transplantation remains a therapeutic management of choice, particularly for patients with widespread or non-resectable disease. Nonetheless, long-term management is essential, involving regular monitoring, imaging studies, and liver function assessments to detect any signs of recurrence or emerging complications. More large-scale, long-term studies are needed to optimize management strategies for HEHE.

1 June 2026 in Biuletyn Głównej Biblioteki Lekarskiej
Verified
Journal Article
Open access
PDF file
ASAleksandra Suchołbiak
Aleksandra Suchołbiak
OMOskar Mikołajczyk
Oskar Mikołajczyk
KBKarolina Baran
Karolina Baran
ASAleksandra Serafin
Aleksandra Serafin
Premenstrual dysphoric disorder (PMDD) is a severe form of menstrual cycle-related mood disorder, significantly impacting mental health, daily functioning, and quality of life. This review article analyzes data on the comorbidity of PMDD with ADHD and/or autism spectrum disorder (ASD). Studies suggest that women with ADHD, or elevated ADHD traits, may be more likely to meet the criteria for PMDD. This association may be particularly pronounced in individuals with comorbid depression and/or anxiety. By contrast, evidence regarding ASD and PMDD remains limited and inconsistent. Although one prospective study, based on the DSM-IV criteria, reported a very high prevalence of late luteal phase dysphoric disorder in autistic women with intellectual disabilities, more recent studies in intellectually capable autistic adolescents and adults did not confirm this association. The findings regarding individuals with co-occurring ASD and ADHD also remain inconclusive. Nevertheless, current evidence warrants cautious interpretation due to methodological limitations. Further research should utilize prospective longitudinal designs, include large, inclusive cohorts (with transgender and gender diverse individuals), and stratify groups according to DSM-5 or ICD-11 criteria. It is important to carefully differentiate between PMDD and premenstrual exacerbation of ADHD symptoms, especially in ADHD population. Furthermore, studies should investigate the potentially shared pathophysiological mechanisms between PMDD and ADHD. Finally, it is important to establish tailored therapeutic protocols for optimizing care in comorbid populations.

13 December 2025 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
AMAleksander Małachowski
Aleksander Małachowski
JWJakub Wójcik
Jakub Wójcik
EBEwa Błaszczak
Ewa Błaszczak
BWBartłomiej Wójcik
Bartłomiej Wójcik
OMOskar Mikołajczyk
Oskar Mikołajczyk
JSJulia Sałata
Julia Sałata
Robotic-assisted surgery has significantly transformed pediatric surgery by enhancing the precision and ergonomics of minimally invasive procedures led to improved outcomes, particularly in complex reconstructive operations. This narrative review evaluates the current landscape, clinical outcomes, technological developments, and broader considerations associated with robotic surgery in children with pediatric urology representing the most developed and well-documented domain of its application. A comprehensive literature search was conducted across PubMed, MEDLINE, and Google Scholar between December 7–10, 2024. Studies involving patients under 18 years, published from 2020 to 2024, were included. After screening 93 articles, 47 met the inclusion criteria and were analyzed for clinical effectiveness, complications, operative metrics, and broader implications. Pyeloplasty and ureteral reimplantation emerged as the most common robotic procedures, demonstrating high success rates and low complication rates. Emerging applications include complex reconstructions, salvage procedures, and image-guided surgery with indocyanine green fluorescence. New robotic platforms, such as single-port systems, aim to improve ergonomics and adaptability for pediatric anatomy, although cost and regulatory barriers persist. Robotic surgery in children offers consistently favorable clinical outcomes with growing procedural diversity. While barriers such as costs and limited pediatric-specific tools remain, innovation and high-volume practices suggest a promising trajectory. Broader adoption will require multicenter prospective trials, standardized reporting, pediatric-specific instrumentation, and cost-reduction strategies.

1 June 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
ASAleksandra Suchołbiak
Aleksandra Suchołbiak
OMOskar Mikołajczyk
Oskar Mikołajczyk
MPMaja Podolak
Maja Podolak
RWRadosław Jan Walkowski
Radosław Jan Walkowski
IGIrmina Grygutis
Irmina Grygutis
KŁKinga Łysak
Kinga Łysak
One-carbon metabolism supports neuropsychiatric function by providing the substrates needed for monoamine neurotransmitter synthesis. In this review, we summarize the available evidence on selected B vitamins and methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms in relation to sleep outcomes, depression, and anxiety in adults. A PubMed search was conducted, through which 27 studies relevant to the review were identified. Observational studies suggest that the relationship between serum folate and sleep is complex, with findings remaining inconsistent across the literature. Nevertheless, improvements in sleep disturbance outcomes following L-methylfolate supplementation among individuals with MTHFR C677T/A1298C polymorphisms provide preliminary support for a link between vitamin B9 metabolism and sleep regulation. In the context of depression and anxiety, observational studies also yielded mixed results. However, interventional studies suggest that supplementation with L-methylfolate at doses exceeding 7.5 mg/day may enhance the response to antidepressant treatment in patients with depression. Furthermore, among patients with major depressive disorder and low-normal vitamin B12 levels, adjunctive therapy with weekly intramuscular injections of 1,000 µg vitamin B12 may improve treatment response. Evidence regarding the role of MTHFR polymorphisms in anxiety and depression remains inconclusive, although some studies suggest that reduced MTHFR activity may be associated with an increased risk of these conditions and that supplementation with a reduced B vitamins and micronutrient complex may offer clinical benefit. In conclusion, vitamin B status and MTHFR polymorphisms may be related to both sleep and anxiety/depressive symptoms. However, because the current evidence remains inconsistent, further large-scale longitudinal studies and well-designed randomized controlled trials are needed.

30 June 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
KBKarolina Baran
Karolina Baran
ASAleksandra Serafin
Aleksandra Serafin
MPMaja Podolak
Maja Podolak
ASAleksandra Suchołbiak
Aleksandra Suchołbiak
OMOskar Mikołajczyk
Oskar Mikołajczyk
UJUrszula JarzęCka
Urszula JarzęCka
Pneumocystis jirovecii pneumonia (PJP) remains a clinically significant opportunistic infection in solid organ transplant (SOT) recipients despite advances in prophylaxis, diagnostics, and treatment. This review aims to summarize current knowledge regarding epidemiology, risk factors, diagnosis, treatment, and prevention of PJP in this population, with particular emphasis on evolving concepts of risk stratification. Although universal trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis has significantly reduced incidence, breakthrough and late-onset infections continue to occur, particularly in the context of fluctuating immunosuppression. The risk of PJP is primarily determined by the net state of immunosuppression rather than time since transplantation alone. Key risk factors include lymphopenia, cytomegalovirus infection or reactivation, treatment of acute rejection with high-dose corticosteroids or lymphocyte-depleting agents, hypogammaglobulinemia, and advanced age. Clinically, PJP in SOT recipients is often acute and rapidly progressive, frequently leading to severe hypoxemic respiratory failure and higher mortality compared with HIV-associated disease. Diagnosis requires integration of clinical findings, high-resolution computed tomography, and microbiological analysis of bronchoalveolar lavage. Molecular assays improve sensitivity, but differentiation between active infection and colonization remains challenging. Serum (1→3)-β-D-glucan may support diagnosis but lacks specificity. Trimethoprim-sulfamethoxazole remains first-line therapy and prophylaxis, while alternative agents are less effective. Emerging molecular and immunological tools may improve risk stratification and guide individualized prophylaxis strategies.